Loading...
NPI 1669590782 · Mountlake Terrace, WA · Retina Specialist (Ophthalmology) Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Tony Huynh is a retina specialist (ophthalmology) physician provider located in Mountlake Terrace, Washington. This profile covers 15 Medicare and 4 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Tony Huynh |
| Address | 6100 219th St Sw Ste 280 |
| City | Mountlake Terrace |
| State | WA |
| ZIP | 98043 |
| Taxonomy | Retina Specialist (Ophthalmology) Physician |
| NPI Enumerated | March 27, 2007 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.4M |
| Medicaid | $190 |
Medicare-dominant revenue mix: this provider reports $1.4M in total Medicare revenue versus $192 in total Medicaid revenue, indicating an effectively single-payer (Medicare-dominant) practice where Medicaid billed activity is present but financially negligible. The disparity in scale is stark on the face of the feeds and suggests payer strategy and financial exposure are overwhelmingly tied to Medicare reimbursement.
High concentration in a few injection codes on Medicare: the top three Medicare codes account for 79.4% of this provider's Medicare revenue, led by J0178 at 65.4% of Medicare revenue, followed by J2777 (8.0%) and 67028 (6.0%). This revenue concentration signals a procedure-focused retina practice whose financial performance is heavily dependent on intravitreal injection therapies rather than diversified office-based services.
Clinical/service-line profile: the code mix (J0178, J2777, Q5128, 67028) and the provider taxonomy as a Retina Specialist are consistent with a practice that delivers high-volume intravitreal anti-VEGF and related retinal therapies. The presence of imaging and E/M volumes—92134 with 1.8K Medicare claims and 99213 with 662 Medicare claims—indicates an operational model combining frequent injections with retinal imaging and ongoing follow-up visits typical of chronic retinal disease management.
Competitive standing by code: for its largest Medicare driver, J0178 ranks #936 of 3204 providers nationally (71th percentile) and is labeled typical/unremarkable volume, so the provider is a solid but not dominant national participant for aflibercept injections. In contrast, retinal imaging 92134 is a clear strength: it ranks #1248 of 26868 providers nationally (95th percentile) and is described as notably above typical national volume, indicating above-average diagnostic throughput relative to peers.
Medicaid billing is limited and low-paid: Medicaid revenue totals $192 and the top three Medicaid codes account for 100.0% of that amount, primarily 92134 (153 claims, $153 revenue) and 99213 (33 claims, $99 revenue). Per-claim Medicaid payments here are very low (92134 at $1/claim and 99213 at $3/claim) compared with Medicare per-claim levels for the same codes, underscoring that Medicaid contributes negligible revenue despite some billed activity.
Mixed national percentile signals across injection types: other injectable therapies appear in the Medicare mix but with modest or variable standing — for example Q5128 produced $80.8K (5.6% of Medicare revenue) and ranks #252 of 373 providers nationally (32th percentile, typical), and J2781 produced $25.2K (1.8%) but ranks #476 of 490 providers nationally (2th percentile, typical). These placements suggest the provider uses a range of retina therapeutics but does not lead nationally in most of those alternative agents.
Established tenure supports continuity of services: the NPI was enumerated on 2007-03-27 (~19 years ago), indicating an established practice presence in Mountlake Terrace, WA. That longevity aligns with the sustained high-volume imaging and injection pattern seen in the Medicare data and suggests an ongoing, stable retina specialty operation rather than a new entrant.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
15 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 1,350 | $690 | $935.5K |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 3,960 | $30 | $114.8K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 890 | $100 | $85.8K |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 370 | $220 | $80.8K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 1,770 | $30 | $56.7K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 660 | $70 | $45.7K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 380 | $100 | $36.2K |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | 210 | $120 | $25.2K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 250 | $100 | $24K |
| J7999 | Compounded drug, not otherwise classified | 130 | $70 | $9.6K |
Showing 1–10 of 15
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 15 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
15 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J2777 | 42 | 50 | 12,780 | $30 | $599.7K |
| J0178 | 28 | 90 | 470 | $680 | $597.2K |
| Q5128 | 9 | 10 | 520 | $220 | $136.6K |
| J2781 | 14 | 10 | 650 | $120 | $88.6K |
| 67028 | 42 | 110 | 550 | $90 | $72.9K |
| 92014 | 131 | 790 | 110 | $80 | $16.8K |
| J7999 | 38 | 70 | 150 | $70 | $15.9K |
| 99214 | 2,122 | 10,860 | 100 | $80 | $13.6K |
| 92134 | 27 | 700 | 70 | $30 | $7.6K |
| 99213 | 157 | 9,690 | 60 | $60 | $6.5K |
Showing 1–10 of 15
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 150 | $1 | $150 |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 30 | $1 | $100 |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 180 | $0 | $0 |
| J0178 | Injection, aflibercept, 1 mg | 30 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Washington providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Washington median
4 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 24 | 30 | 550 | $930 | $892.3K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,580 | 1,860 | 610 | $40 | $295.5K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 42 | 60 | 710 | $40 | $81.7K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 58 | 100 | 240 | $10 | $22.2K |
Other providers in the same ZIP code as Tony Huynh, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Maxim Healthcare Services, Inc. | WA | Home Health Agency | $0 | $18.2M |
| Dependable Medical Equipment, Inc. | WA | Durable Medical Equipment & Medical Supplies | $0 | $3.1M |
| Puget Sound Kidney Centers | WA | End-Stage Renal Disease (ESRD) Treatment Clinic/Center | $0 | $2.9M |
| Proliance Surgeons Inc P S | WA | Ambulatory Surgical Clinic/Center | $617.8K | $0 |
| Mercury Pharmacy Services Inc | WA | Long Term Care Pharmacy | $385.5K | $211.9K |
| Karny Jacoby | WA | Urology Physician | $61.3K | $0 |
| Mark Silver | WA | Specialist | $55.5K | $0 |
| Bethell Assefa | WA | Psychiatric/Mental Health Nurse Practitioner | $34.5K | $0 |
| Mandi Bainton | WA | Surgical Physician Assistant | $32.1K | $0 |
| Erin Chaney | WA | Adult Health Nurse Practitioner | $23K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.